Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
40 hedge funds and large institutions have $5.84M invested in Vyant Bio, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 8 closing their positions.
25,733% more call options, than puts
Call options by funds: $775K | Put options by funds: $3K
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
25% more funds holding
Funds holding: 32 → 40 (+8)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
44% less capital invested
Capital invested by funds: $10.5M → $5.84M (-$4.63M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$891K |
| 2 |
Renaissance Technologies
New York
|
+$366K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$322K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$305K |
| 5 |
Millennium Management
New York
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$1.06M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.02M |
| 3 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$741K |
| 4 |
DII
Domini Impact Investments
New York
|
-$235K |
| 5 |
RA
Royce & Associates
New York
|
-$136K |
VYNT Hedge Fund Activity: Q4 2015 in Review
40 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2015, worth a combined $5.84M — down 44% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VYNT positions and 8 closed out — a net gain of 8 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was Perkins Capital Management, opening a new position worth an estimated $891K. The largest seller was Allianz Asset Management, exiting entirely with an estimated $1.06M sold.
- 40 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2015, up from 32 in Q3 2015.
- Funds reported $5.84M of Vyant Bio, Inc. Common Stock stock for Q4 2015, down 44% quarter-over-quarter.
- 16 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2015 and 8 closed out, a net change of +8 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2015 was Perkins Capital Management, an estimated $891K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2015 was Allianz Asset Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q4 2015.